Trial of Docetaxel-samarium in Patients With Hormone-refractory Advanced Prostate Cancer

Inclusion Criteria: * Patients older than 18 years and less than 80 years * Histologically-proven adenocarcinoma of the prostate * Evidence of bone metastases and progressive, hormone-refractory, disease * No previous chemotherapy * No previous radiotherapy, except radiotherapy directed to the prostate and/or to a single bony lesion * No previous carcinoma, except basal-cell carcinoma of the skin * Adequate renal function: measured or calculated creatinine clearance \> 60 ml/min * Absolute granulocyte count ≥ 1,500/mm3, platelets ≥ 100,000 mm3, bilirubin ≤ 1.5 fold the upper normal value * Signed informed consent. Exclusion Criteria: * Patients infected by the Human Immunodeficiency Virus (HIV) * Patients who do not fit inclusion criteria